Thanks SoT,
Hopkins identified two paradigm shifts during the course of the interview;
1. identification of target not by type of cancer e.g. breast cancer but by its genotype - the genotype being targeted is found in over 50% of cancers.
2. target is not an effector or cause of the cancer but a key driver, one which doesn't evolve but remains constant in a 'sea of change' thereby making it an ideal target.
The discovery of an efficient delivery system could well be described as a third paradigm shift.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |